Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | NEK2 | P51955 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | CTSB | P07858 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5316300 | 0.90 | RHOA (0.41) | MAPTOPRK1TDP1NEK2ALDH1A1 | |
| SCHEMBL4103444 | 0.90 | RHOA (0.41) | MAPTOPRK1TDP1NEK2ALDH1A1 | |
| SCHEMBL4097357 | 0.86 | KDM4E (0.42) | MAPTNEK2KDM4EALDH1A1TP53 | |
| SCHEMBL4110344 | 0.85 | NEK2 (0.45) | MAPTOPRK1NEK2KDM4ELMNA | |
| SCHEMBL5610909 | 0.85 | KDM4E (0.41) | MAPTNEK2KDM4EALDH1A1LMNA | |
| SCHEMBL4103864 | 0.84 | KDM4E (0.40) | MAPTNEK2KDM4EALDH1A1LMNA | |
| SCHEMBL4109151 | 0.84 | OPRK1 (0.40) | MAPTOPRK1ALDH1A1HTTTP53 | |
| SCHEMBL4098866 | 0.83 | KDM4E (0.40) | MAPTOPRK1NEK2KDM4EALDH1A1 | |
| SCHEMBL4098179 | 0.83 | NEK2 (0.39) | MAPTOPRK1NEK2KDM4EALDH1A1 | |
| SCHEMBL4104992 | 0.82 | NEK2 (0.39) | MAPTOPRK1NEK2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227555-A2 | Novel Pyridine Compounds | ASTRAZENECA AB (SE) | 2009-09-10 | — | — | US | disclosed |
| US-20090042852-A1 | Novel Pyridine Compounds | ASTRAZENECA AB (SE) | 2009-02-12 | — | — | US | disclosed |
| CN-101137643-A | Novel pyridine compounds | ASTRAZENECA AB (SE) | 2008-03-05 | — | — | CN | disclosed |
| EP-1836189-A1 | NOVEL PYRIDINE COMPOUNDS | AstraZeneca AB (SE) | 2007-09-26 | — | — | EP | disclosed |
| WO-2006073361-A9 | NOVEL PYRIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2007-08-02 | — | — | WO | disclosed |
| WO-2006073361-A1 | NOVEL PYRIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2006-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042852-A1 | Novel Pyridine Compounds | P2RY12, P2RY11, P2RY1 | MAPT 3696/4885OPRK1 737/4885TDP1 1481/4885 |
| US-20090227555-A2 | Novel Pyridine Compounds | P2RY12, P2RY1, P2RY11 | MAPT 4295/4885OPRK1 1185/4885TDP1 1385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.